Publicacions en col·laboració amb investigadors/es de Lund University (6)

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2018

  1. Complement C4d-specific antibodies for the diagnosis of lung cancer

    Oncotarget, Vol. 9, Núm. 5, pp. 6346-6355

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2009

  1. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack

    Cancer Immunology, Immunotherapy, Vol. 58, Núm. 11, pp. 1771-1780

2008

  1. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors

    Molecular Immunology, Vol. 45, Núm. 1, pp. 169-179